| Literature DB >> 31460375 |
Norma Flores-Holguín1, Juan Frau2, Daniel Glossman-Mitnik1,2.
Abstract
A well-behaved model chemistry previously validated for the study of the chemical reactivity of peptides was considered for the calculation of the molecular properties and structures of a group of five new antifungal tripeptides, namely (2R)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]propanamido]-5-[(diaminomethylidene)amino]pentanoic acid, (2S)-2-[(2S)-2-[(2S)-2-amino-3-phenyl propanamido]propanamido]-3-(4-hydroxyphenyl)propanoic acid, (2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylbutanamido]-3-(4-hydroxyphenyl)propanoic acid, (2R)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanoic acid, and (2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-(4-hydroxyphenyl)propanoic acid, according to their amino acid sequences. A methodology based on conceptual density functional theory was chosen for the determination of the reactivity descriptors. The molecular active sites were associated with the active regions of the molecules that were associated with the nucleophilic, electrophilic, and radical Fukui functions. Additionally, the pK a values for the different peptides are predicted with great accuracy, which constitutes a useful knowledge for the process of drug design. Finally, the bioactivity scores for the new antifungal peptides are predicted through a homology methodology relating them with the calculated reactivity descriptors.Entities:
Year: 2019 PMID: 31460375 PMCID: PMC6682088 DOI: 10.1021/acsomega.9b01463
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1Graphical sketches of the molecular structures of the five antifungal tripeptides showing the numbering of the atoms: (a) FAR; (b) FAY; (c) FVY; (d) FWC; and (e) FWY, where green is used for C, red for O, blue for N, and gray for H.
HOMO and LUMO Orbital Energies (in eV), the HOMO–LUMO Gap (Also in eV), and the Maximum Absorption Wavelengths λmax (in nm) of the Five Antifungal Tripeptides, FAR, FAY, FVY, FWC, and FWY, Predicted by the MN12SX/Def2TZVP/H2O Model Chemistry
| HOMO | LUMO | HOMO–LUMO gap | λmax | |
|---|---|---|---|---|
| FAR | –7.051 | –2.838 | 4.213 | 294 |
| FAY | –6.223 | –3.285 | 2.938 | 422 |
| FVY | –6.254 | –1.753 | 4.501 | 275 |
| FWC | –5.634 | –1.733 | 3.901 | 318 |
| FWY | –5.634 | –3.184 | 2.450 | 506 |
Global Reactivity Descriptors of the Five New Antifungal Tripeptides FAR, FAY, FVY, FWC, and FWY (in eV), Calculated with the MN12SX/Def2TZVP/H20 Model Chemistry
| molecule | electronegativity | global hardness | electrophilicity |
|---|---|---|---|
| FAR | 4.945 | 4.212 | 2.902 |
| FAY | 4.754 | 2.938 | 3.846 |
| FVY | 4.003 | 4.501 | 1.780 |
| FWC | 3.683 | 3.901 | 1.739 |
| FWY | 4.409 | 2.450 | 3.968 |
Figure 2Graphical representation of the electrophilic Fukui functions f–(r) (left column) and nucleophilic Fukui functions f+(r) (right column) of the five antifungal tripeptides.
Local Reactivity Descriptors for the Antifungal Tripeptides FAR, FAY, FVY, FWC, and FWY, Calculated with the MN12SX/Def2TZVP/H2O Model Chemistry: Condensed DD Δf, Nucleophilic Parr Function P+, and Electrophilic Parr Function P–
| atom | Δ | ||
|---|---|---|---|
| 11C | 26.62 | 0.383 | 0.000 |
| 51N | –51.22 | 0.000 | 0.713 |
| 29C | –22.96 | 0.013 | 0.459 |
| 41C | 12.68 | 0.316 | 0.126 |
| 8C | 8.23 | 0.145 | 0.002 |
| 45C | –23.25 | 0.038 | 0.384 |
| 29C | –22.55 | 0.001 | 0.434 |
| 41C | 15.14 | 0.325 | 0.084 |
| 29C | –22.96 | 0.013 | 0.459 |
| 41C | 12.68 | 0.316 | 0.126 |
pKa’s of the Antifungal Tripeptides FAR, FAY, FVY, FWC, and FWY
| molecule | p |
|---|---|
| FAR | 12.83 |
| FAY | 13.88 |
| FVY | 12.59 |
| FWC | 13.08 |
| FWY | 11.44 |
Bioactivity Scores of the Antimicrobial Peptides FAR, FAY, FVY, FWC, and FWY Calculated on the Basis of the GPCR Ligand, Ion Channel Modulator, Nuclear Receptor Ligand, Kinase Inhibitor, Protease Inhibitor, and Enzyme Inhibitor Interactions
| molecule | GPCR ligand | ion channel modulator | kinase inhibitor | nuclear receptor ligand | protease inhibitor | enzyme inhibitor |
|---|---|---|---|---|---|---|
| FAR | 0.42 | 0.24 | 0.08 | 0.08 | 0.64 | 0.47 |
| FAY | 0.35 | 0.18 | 0.10 | 0.17 | 0.67 | 0.38 |
| FVY | 0.32 | 0.15 | 0.07 | 0.15 | 0.67 | 0.36 |
| FWC | 0.43 | 0.29 | 0.09 | 0.07 | 1.09 | 0.51 |
| FWY | 0.39 | 0.21 | 0.07 | 0.11 | 0.78 | 0.35 |